Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H20N.HO |
Molecular Weight | 147.2584 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[OH-].CC[N+](CC)(CC)CC
InChI
InChIKey=LRGJRHZIDJQFCL-UHFFFAOYSA-M
InChI=1S/C8H20N.H2O/c1-5-9(6-2,7-3)8-4;/h5-8H2,1-4H3;1H2/q+1;/p-1
Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. Tetraethylammonium blocks of apamin-sensitive and insensitive Ca2(+)-activated K+ channels. It is a weak agonist of the nicotinic receptor. Tetraethylammonium produces transient reductions in blood pressure. Tetraethylammonium hydroxide is used as a soluble source of hydroxide ions and in the synthesis of ionic organic compounds.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3137264 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12824448 |
|||
Target ID: CHEMBL2096673 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1698974 |
3.1 mM [Kd] | ||
Target ID: CHEMBL5505 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1698974 |
260.0 µM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Fosglutamina B6 Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
375 mg 1 times / day single, intravenous (mean) Studied dose Dose: 375 mg, 1 times / day Route: intravenous Route: single Dose: 375 mg, 1 times / day Sources: |
healthy, adult n = 7 Health Status: healthy Age Group: adult Sex: M+F Population Size: 7 Sources: |
Other AEs: Paralysis, Drowsiness... |
41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Other AEs: Dysphagia, Dysarthria... Other AEs: Dysphagia (66.7%) Sources: Dysarthria (66.7%) Nasal congestion (66.7%) Respiration labored (66.7%) Weakness generalized (100%) Dry mouth (100%) Numbness (100%) Ptosis (100%) Mydriasis (100%) Vasomotor collapse (33.3%) Asthma (33.3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Drowsiness | 14.3% | 375 mg 1 times / day single, intravenous (mean) Studied dose Dose: 375 mg, 1 times / day Route: intravenous Route: single Dose: 375 mg, 1 times / day Sources: |
healthy, adult n = 7 Health Status: healthy Age Group: adult Sex: M+F Population Size: 7 Sources: |
Paralysis | 14.3% | 375 mg 1 times / day single, intravenous (mean) Studied dose Dose: 375 mg, 1 times / day Route: intravenous Route: single Dose: 375 mg, 1 times / day Sources: |
healthy, adult n = 7 Health Status: healthy Age Group: adult Sex: M+F Population Size: 7 Sources: |
Dry mouth | 100% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Mydriasis | 100% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Numbness | 100% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Ptosis | 100% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Weakness generalized | 100% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Asthma | 33.3% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Vasomotor collapse | 33.3% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Dysarthria | 66.7% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Dysphagia | 66.7% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Nasal congestion | 66.7% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Respiration labored | 66.7% | 41 mg/kg 1 times / day single, intravenous Studied dose Dose: 41 mg/kg, 1 times / day Route: intravenous Route: single Dose: 41 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: hypertension Age Group: adult Population Size: 3 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Kv3.1-Kv3.2 channels underlie a high-voltage-activating component of the delayed rectifier K+ current in projecting neurons from the globus pallidus. | 1999 Sep |
|
Changes in neuronal excitability and synaptic function in a chronic model of temporal lobe epilepsy. | 2001 |
|
[Spontaneous transient outward currents in smooth muscle cells of the rat tail artery]. | 2001 |
|
Syntheses of halogenated ethenyl isocyanide chromium complexes as organometallic precursor molecules for ethenyl and ethynyl isocyanides. | 2001 |
|
Inotrophic effects of the K(+) channel blocker TEA on dystrophic (mdx and dy/dy) mouse diaphragm. | 2001 Apr |
|
Short term hypercholesterolemia alters N(G)-nitro-L-arginine- and indomethacin-resistant endothelium-dependent relaxation by acetylcholine in rabbit renal artery. | 2001 Feb |
|
Fusicoccin- and IAA-induced elongation growth share the same pattern of K+ dependence. | 2001 Feb |
|
Angiotensin II relaxes microvessels via the AT(2) receptor and Ca(2+)-activated K(+) (BK(Ca)) channels. | 2001 Feb |
|
The effect of proteolytic enzymes on the alpha9-nicotinic receptor-mediated response in isolated frog vestibular hair cells. | 2001 Feb |
|
BK channels in human glioma cells. | 2001 Feb |
|
Comparison of spontaneous and noradrenaline-evoked non-selective cation channels in rabbit portal vein myocytes. | 2001 Feb 1 |
|
Theta-frequency bursting and resonance in cerebellar granule cells: experimental evidence and modeling of a slow k+-dependent mechanism. | 2001 Feb 1 |
|
Selective inhibition of amine oxidases differently potentiate the hypophagic effect of benzylamine in mice. | 2001 Feb 9 |
|
Determination of ambroxol or bromhexine in pharmaceuticals by capillary isotachophoresis. | 2001 Jan |
|
Number of K(Ca) channels underlying spontaneous miniature outward currents (SMOCs) in mudpuppy cardiac neurons. | 2001 Jan |
|
Shear stress-induced vasodilation in porcine coronary conduit arteries is independent of nitric oxide release. | 2001 Jun |
|
Multiple binding sites for melatonin on Kv1.3. | 2001 Mar |
|
Multiple Ca(2+)-dependent modulators mediate alkalosis-induced vasodilation in newborn piglet lungs. | 2001 Mar |
|
Chloride channels regulate HIT cell volume but cannot fully account for swelling-induced insulin secretion. | 2001 May |
|
Mechanism underlying slow kinetics of the OFF gating current in Shaker potassium channel. | 2001 May |
|
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. | 2001 May |
|
Effects of P-glycoprotein on cell volume regulation in mouse proximal tubule. | 2001 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00166166
5 min infusion of Tetraethylammonium at 1 mg/min
Route of Administration:
Intra-arterial
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12824448
TEA is a weak agonist of the nicotinic receptor. No single-channel clusters were observed at concentrations as high as 5 mM TEA or in the presence of a mutation which selectively increases the efficacy of the receptor. When coapplied with 1 mM carbamylcholine (CCh), TEA decreased the effective opening rate demonstrating that it acts as a competitive antagonist of CCh-mediated activation. Kinetic analysis of currents elicited by CCh and TEA allowed an estimate of receptor affinity for TEA of about 1 mM, while an upper limit of 10 s-1 could be set for the wild-type channel-opening rate constant for receptors activated by TEA alone. At millimolar concentrations, TEA inhibited nicotinic receptor currents by depressing the single-channel amplitude. The effect had an IC50 of 2-3 mM, depending on the conditions of the experiment, and resembled a standard open-channel block.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
4215
Created by
admin on Fri Dec 15 19:50:49 GMT 2023 , Edited by admin on Fri Dec 15 19:50:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Tetraethylammonium hydroxide
Created by
admin on Fri Dec 15 19:50:49 GMT 2023 , Edited by admin on Fri Dec 15 19:50:49 GMT 2023
|
PRIMARY | |||
|
6509
Created by
admin on Fri Dec 15 19:50:49 GMT 2023 , Edited by admin on Fri Dec 15 19:50:49 GMT 2023
|
PRIMARY | |||
|
77-98-5
Created by
admin on Fri Dec 15 19:50:49 GMT 2023 , Edited by admin on Fri Dec 15 19:50:49 GMT 2023
|
PRIMARY | |||
|
DTXSID30883222
Created by
admin on Fri Dec 15 19:50:49 GMT 2023 , Edited by admin on Fri Dec 15 19:50:49 GMT 2023
|
PRIMARY | |||
|
1648695
Created by
admin on Fri Dec 15 19:50:49 GMT 2023 , Edited by admin on Fri Dec 15 19:50:49 GMT 2023
|
PRIMARY | RxNorm | ||
|
201-073-3
Created by
admin on Fri Dec 15 19:50:49 GMT 2023 , Edited by admin on Fri Dec 15 19:50:49 GMT 2023
|
PRIMARY | |||
|
RA8VU41B1F
Created by
admin on Fri Dec 15 19:50:49 GMT 2023 , Edited by admin on Fri Dec 15 19:50:49 GMT 2023
|
PRIMARY | |||
|
m10616
Created by
admin on Fri Dec 15 19:50:49 GMT 2023 , Edited by admin on Fri Dec 15 19:50:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
DBSALT000176
Created by
admin on Fri Dec 15 19:50:49 GMT 2023 , Edited by admin on Fri Dec 15 19:50:49 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
ACTIVE MOIETY
SUBSTANCE RECORD